Non-contiguous finished genome sequence and description of *Brevibacillus massiliensis* sp. nov.

Perrine Hugon, Ajay Kumar Mishra, Jean-Christophe Lagier, Thi Thien Nguyen, Carine Couderc, Didier Raoult and Pierre-Edouard Fournier

1Aix-Marseille Université, URMI, Faculté de médecine, France

† These two authors have equal contribution

* Corresponding author: Pierre-Edouard Fournier (pierre-edouard.fournier@univmed.fr)

**Keywords:** *Brevibacillus massiliensis*, genome, culturomics, taxono-genomics

*Brevibacillus massiliensis* strain phRT sp. nov. is the type strain of *B. massiliensis* sp. nov., a new species within the genus *Brevibacillus*. This strain was isolated from the fecal flora of a woman suffering from morbid obesity. *B. massiliensis* is a Gram-positive aerobic rod-shaped bacterium. Here we describe the features of this organism, together with the complete genome sequence and annotation. The 5,051,018 bp long genome (1 chromosome but no plasmid) contains 5,051 protein-coding and 84 RNA genes, and exhibits a G+C content of 53.1%.

**Introduction**

*Brevibacillus massiliensis* strain phRT (= CSUR P177 = DSM 25447) is the type strain of *B. massiliensis* sp. nov. This bacterium is a Gram-positive, spore-forming, indole negative, aerobic and motile bacillus that was isolated from the stool of a 26-year-old woman suffering from morbid obesity. The strain was isolated as part of a study aiming at individually cultivating all species within human feces [1]. The current approach to classification of prokaryotes, often referred to as polyphasic taxonomy, relies on a combination of phenotypic and genotypic characteristics [2]. However, as more than 3,000 bacterial genomes have been sequenced to date [3] and the cost of genomic sequencing is decreasing, we recently proposed to integrate genomic information in the description of new bacterial species [4-15].

The genus *Brevibacillus* (Shilda et al. 1996) was created in 1996 by reclassification of 10 *Bacillus* species, on the basis of 16S rDNA gene sequence analysis [16]. To date, this genus is made of 18 species [17], including *B. agri*, *B. brevis*, *B. centrosporus*, *B. choshinensis*, *B. parabrevis*, *B. reuszeri*, *B. formosus*, *B. borstelensis*, *B. laterosporus*, and *B. thermoruber* [16], *B. invocatus* [18], *B. limnophilus* [19], *B. levickii* [20], *B. ginsengisoli* [21], *B. panacihumi* [22], *B. fluminis* in [23], and *B. nitrificans* [24]. Members of the genus *Brevibacillus* are environmental bacteria and were mostly isolated from soil [22,25]. In addition, *B. brevis* and *B. centrosporus* were isolated from indoor dust in schools, day care centers for children and animal sheds [26], and fecal flora of children, respectively [27]. However, several *Brevibacillus* species are also frequently isolated from humans, notably in nosocomial infections, causing breast abscess, pneumonia [18], peritonitis [28] and endophthalmitis [29].

Here we present a summary classification and a set of features for *B. massiliensis* sp. nov. strain phRT (= CSUR P177 = DSM 25447), together with the description of the complete genomic sequencing and annotation. These characteristics support the circumscription of the *B. massiliensis* species.

**Classification and features**

A stool sample was collected from a 26-year-old woman living in Marseille (France). She suffered from morbid obesity and had a body mass index of 48.2 (118.8 kg, 1.57 meter). At the time of stool sample collection she was not under medication or on a diet. The patient gave an informed and signed consent. This study and the assent procedure were approved by the Ethics Committee of the Institut Fédératif de Recherche IFR48, Faculty of Medicine, Marseille, France (agreement 11-017). The fecal specimen was preserved at -80°C after collection. Strain phRT (Table 1) was isolated in 2011 by aerobic cultivation on M17 agar medium (Oxoid, Basingstoke, England).
Brevibacillus massiliensis sp. nov.

This strain exhibited a nucleotide sequence similarity with Brevibacillus species ranging from 94% with B. centrosporus [18] to 96% with B. reuszeri, B. parabrevis, B. invocatus, B. brevis, B. borstelensis [18], B. panachumi [22], B. levickii [20], (Figure 1). This latter value was lower than the 98.7% 16S rRNA gene sequence threshold recommended by Stackebrandt and Ebers to delineate a new species without carrying out DNA-DNA hybridization [40].

Different growth temperatures (25, 30, 37, 45°C [Table 2]) were tested; no growth occurred at 25°C, growth occurred between 30 and 45°C, and optimal growth was observed at 37°C. Grey colonies were 0.8 mm to 1 mm in diameter on blood-enriched Columbia agar and Brain Heart Infusion (BHI) agar. Growth of the strain was tested under anaerobic and microaerophilic conditions using GENbag anaer and GENbag microaer systems, respectively (BioMerieux), and in the presence of air, with or without 5% CO₂. Growth was obtained aerobically. A weak growth was observed with 5% CO₂, but no growth occurred in microaerophilic and anaerobic conditions. Gram staining showed Gram-positive rods (Figure 2). The motility test was positive. Cell diameters ranged from 0.61 µm to 0.80 µm, with a mean diameter of 0.74 µm, and from 2.60µm to 7.30 µm long, with a mean length of 4.3µm in electron microscopy. Peritrichous flagellae were also observed (Figure 3).

Table 1. Classification and general features of Brevibacillus massiliensis strain phRT according to the MIGS recommendations [42]

| MIGS ID   | Property                  | Term                    | Evidence codea   |
|-----------|---------------------------|-------------------------|-----------------|
| MIGS-6.3  | Salinity                  | growth in BHI medium + 5% NaCl | IDA             |
| MIGS-22   | Oxygen requirement        | aerobic                 | IDA             |
| MIGS-6    | Habitat                   | human gut               | IDA             |
| MIGS-15   | Biotic relationship       | free living             | IDA             |
| MIGS-14   | Isolation                 | human feces             | IDA             |
| MIGS-4    | Geographic location       | France                  | IDA             |
| MIGS-5    | Sample collection time    | January 2011            | IDA             |
| MIGS-4.1  | Latitude                  | 43.296482               | IDA             |
| MIGS-4.2  | Longitude                 | 5.36978                 | IDA             |
| MIGS-4.3  | Depth                     | surface                 | IDA             |
| MIGS-4.4  | Altitude                  | 0 m above sea level     | IDA             |

Evidence codes - IDA: Inferred from Direct Assay; TAS: Traceable Author Statement (i.e., a direct report exists in the literature); NAS: Non-traceable Author Statement (i.e., not directly observed for the living, isolated sample, but based on a generally accepted property for the species, or anecdotal evidence). These evidence codes are from the Gene Ontology project [39]. If the evidence is IDA, then the property was directly observed for a live isolate by one of the authors or an expert mentioned in the acknowledgements.
Figure 1. Phylogenetic tree highlighting the position of *Brevibacillus massiliensis* strain phR relative to other type strains within the *Brevibacillus* genus. GenBank accession numbers are indicated in parentheses. Sequences were aligned using CLUSTALW, and phylogenetic inferences obtained using the maximum-likelihood method within MEGA program. Numbers at the nodes are percentages of bootstrap values obtained by repeating the analysis 500 times to generate a majority consensus tree. *Alicyclobacillus acidocaldarius* was used as outgroup. The scale bar represents a 2% nucleotide sequence divergence.

Strain phR exhibited catalase and oxidase activities. Using an API ZYM strip (BioMerieux, Marcy l’Etoile), positive reactions were obtained for alkaline phosphatase, cystine arylamidase, acid phosphatase and naphtol-AS-BI-phosphohydrolase. Weak reactions were obtained for esterase, esterase lipase, leucine arylamidase, valine arylamidase, and α-chymotrypsin. Using an API Coryne strip (BioMerieux), positive reactions were obtained for pyrazinamidase and alkaline phosphatase. No sugar fermentation was observed using API 50CH (Biomerieux).

*B. massiliensis* is susceptible to penicillin G, amoxicillin, amoxicillin + clavulanic acid, ceftriaxone, imipenem, erythromycin, doxycycline, rifampicin, vancomycin, ciprofloxacin, gentamicin, nitrofurantoin and resistant to metronidazole and trimetoprim + sulfamethoxazole. By comparison with *B. borstelensis*, its phylogenetically-closest neighbor, *B. massiliensis* differed in fumarate, phenylacetate and glutamate activities [18]. By comparison with *B. brevis*, *B. massiliensis* differed in alkaline and acid phosphatase production, nitrate reductase, esterase, esterase lipase, leucine arylamidase, cystine arylamidase and valine arylamidase production. By comparison with *B. agri*, *B. massiliensis* differed in oxidase production.
**Table 2.** Differential characteristics of *B. massiliensis* sp. nov strain ph1<sup>T</sup>, *B. agri* strain NRRL NRS-1219, *B. laterosporus* strain JCM 2496 and *B. brevis* NBRC 15304<sup>T</sup>.

| Properties                          | *B. massiliensis* | *B. agri* | *B. laterosporus* | *B. brevis* |
|-------------------------------------|-------------------|------------|-------------------|-------------|
| Cell diameter (µm)                  | 0.74              | 0.75       | na                | 0.50        |
| Oxygen requirement                  | aerobic           | aerobic    | aerobic, facultative anaerobic | aerobic |
| Gram stain                          | +                 | +          | var               | +           |
| Salt requirement                    | na                | na         | na                | -           |
| Motility                            | +                 | +          | +                 | +           |
| Endospore formation                 | na                | +          | +                 | +           |

**Production of**

|                          | *B. massiliensis* | *B. agri* | *B. laterosporus* | *B. brevis* |
|--------------------------|-------------------|------------|-------------------|-------------|
| Alkaline phosphatase     | +                 | na         | na                | -           |
| Acid phosphatase         | +                 | na         | na                | -           |
| Catalase                 | +                 | +          | +                 | +           |
| Oxidase                  | +                 | -          | na                | +           |
| Nitrate reductase        | -                 | -          | na                | +           |
| Urease                   | -                 | -          | na                | -           |
| α-galactosidase          | -                 | na         | na                | -           |
| β-galactosidase          | -                 | na         | na                | -           |
| β-glucuronidase          | -                 | na         | na                | -           |
| α-glucosidase            | -                 | na         | na                | -           |
| N-acetyl-β-glucosaminidase | -               | na         | na                | -           |
| Indole                   | -                 | -          | -                 | -           |
| Esterase                 | w                 | na         | na                | +           |
| Esterase lipase          | w                 | na         | na                | +           |
| Naphthyl-AS-BI-phosphohydrolase | +           | na         | na                | +           |
| Arginine arylamidase     | -                 | na         | na                | na          |
| Arginine dihydrolase     | -                 | na         | na                | -           |
| Glutamyl glutamic acid arylamidase | -           | na         | na                | na          |
| Phenylalanine arylamidase | -                 | na         | na                | na          |
| Leucine arylamidase      | w                 | na         | na                | -           |
| Cystine arylamidase      | +                 | na         | na                | -           |
| Valine arylamidase       | w                 | na         | na                | -           |
| Glycine arylamidase      | -                 | na         | na                | na          |
| Histidine arylamidase    | -                 | na         | na                | na          |
| Serine arylamidase       | -                 | na         | na                | na          |

**Utilization of**

|                          | *B. massiliensis* | *B. agri* | *B. laterosporus* | *B. brevis* |
|--------------------------|-------------------|------------|-------------------|-------------|
| D-mannose                | -                 | na         | na                | -           |

**Habitat**

|                          | human gut         | environment | environment | environment |
|--------------------------|-------------------|-------------|-------------|-------------|
Matrix-assisted laser-desorption/ionization time-of-flight (MALDI-TOF) MS protein analysis was carried out as previously described [41]. Briefly, a pipette tip was used to pick an isolated bacterial colony from a culture agar plate and spread it as a thin film on a MTP 384 MALDI-TOF target plate (Bruker Daltonics, Germany). Twelve distinct deposits were done for strain phRT from twelve isolated colonies. Each smear was overlaid with 2µL of matrix solution (saturated solution of alpha-cyano-4-hydroxycinnamic acid) in 50% acetonitrile, 2.5% tri-fluoracetic acid, and allowed to dry for five minutes. Measurements were performed with a Microflex spectrometer (Bruker). Spectra were recorded in the positive linear mode for the mass range of 2,000 to 20,000 Da (parameter settings: ion source 1 (IS1), 20kV; IS2, 18.5 kV; lens, 7 kV). A spectrum was obtained after 675 shots at a variable laser power. The time of acquisition was between 30 seconds and 1 minute per spot. The twelve phRT spectra were imported into the MALDI BioTyper software (version 2.0, Bruker) and analyzed by standard pattern matching (with default parameter settings) against the main spectra of 3,769 bacteria, including spectra from nine validly published Brevibacillus species that were used as reference data in the BioTyper database (updated March 15th, 2012). The method of identification includes the m/z from 3,000 to 15,000 Da. For every spectrum, 100 peaks at most were taken into account and compared with the spectra in the database. A score enabled the presumptive identification and discrimination of the tested species from those in a database: a score ≥ 2 with a validated species enabled the identification at the species level; a score ≥ 1.7 but < 2 enabled the identification at the genus level; and a score < 1.7 did not enable any identification. For strain phRT, no significance score was obtained, thus suggesting that our isolate was not a member of a known species. We incremented our database with the spectrum from strain phRT (Figure 4). Finally, the gel view allows us to highlight the spectra differences with other of Brevibacillus genera members (Figure 5).

Figure 2. Gram staining of B. massiliensis strain phRT
Figure 3. Transmission electron microscopy of *B. massiliensis* strain phR¹, using a Morgani 268D (Philips) at an operating voltage of 60kV. The scale bar represents 1 µm.

Figure 4. Reference mass spectrum from *B. massiliensis* strain phR¹. Spectra from 12 individual colonies were compared and a reference spectrum was generated.
Figure 5. Gel view comparing *Brevibacillus massiliensis* phR1 spectra with other members into *Brevibacillus* genera (*Brevibacillus reuszeri*, *Brevibacillus parabrevis*, *Brevibacillus laterosporus*, *Brevibacillus formosus*, *Brevibacillus choshinensis*, *Brevibacillus centrosporus*, *Brevibacillus brevis*, *Brevibacillus borstelensis*, *Brevibacillus agri*). The Gel View displays the raw spectra of all loaded spectrum files arranged in a pseudo-gel like look. The x-axis records the m/z value. The left y-axis displays the running spectrum number originating from subsequent spectra loading. The peak intensity is expressed by a Gray scale scheme code. The color bar and the right y-axis indicates the relation between the color a peak is displayed with and the peak intensity in arbitrary units.

**Genome sequencing information**

**Genome project history**

The organism was selected for sequencing on the basis of its phylogenetic position and 16S rRNA similarity to other members of the *Brevibacillus* genus, and is part of a study of the human digestive flora aiming at isolating all bacterial species within human feces. It was the fifth genome of a *Brevibacillus* species and the first genome of *Brevibacillus massiliensis* sp. nov. The Genbank accession number is CAGW0000000 and consists of 132 contigs. Table 3 shows the project information and its association with MIGS version 2.0 compliance [42].

**Growth conditions and DNA isolation**

*B. massiliensis* sp. nov. strain phR1, (= CSUR P177 = DSM 25447), was grown aerobically on M17 agar medium at 37°C. Five petri dishes were spread and resuspended in 3×100µl of G2 buffer (EZ1 DNA Tissue kit, Qiagen). A first mechanical lysis was performed using glass powder on a Fastprep-24 device (Sample Preparation system, MP Biomedicals, USA) during 2×20 seconds. DNA was then treated with 2.5 µg/µL (30 minutes at 37°C) and extracted using a BioRobot EZ 1 Advanced XL (Qiagen). The DNA was then concentrated and purified on a Qiamp kit (Qiagen). The yield and the concentration was measured by the Quant-it Picogreen kit (Invitrogen) on the Genios_Tecan fluorometer at 36.8 ng/µl.
**Table 3. Project information**

| MIGS ID | Property              | Term                          |
|---------|-----------------------|-------------------------------|
| MIGS-31 | Finishing quality     | High-quality draft            |
| MIGS-28 | Libraries used        | One 454 paired end 3-kb library |
| MIGS-29 | Sequencing platforms  | 454 GS FLX Titanium           |
| MIGS-31.2| Fold coverage        | 54.2×                        |
| MIGS-30 | Assemblers            | Newbler version 2.5.3         |
| MIGS-32 | Gene calling method   | Prodigal                      |
|         | INSDC ID              | PRJEA82077                   |
|         | Genbank ID            | CAGW00000000                  |
|         | Genbank Date of Release| May 30, 2012                |
|         | Project relevance     | Study of the human gut microbiome |

**Genome sequencing and assembly**

A 3kb paired-end sequencing strategy (Roche, Meylan, France) was used. Five µg of DNA was mechanically fragmented on the Hydroshear device (Digilab, Holliston, MA, USA) with an enrichment size at 3-4kb. The DNA fragmentation was visualized through an Agilent 2100 BioAnalyzer on a DNA labchip 7500 with an optimal size of 3.2 kb. The library was constructed according to the 454 GS FLX Titanium paired end protocol. Circuclarization and nebulization were performed and generated a pattern with an optimal at 555 bp. After PCR amplification through 17 cycles followed by double size selection, the single stranded paired-end library was then quantified on the Quant-it Ribogreen kit (Invitrogen) on the Genios_Tecan fluorometer at 21 pg/µL. The library concentration equivalence was calculated as 6.94e+07 molecules/µL. The library was stored at -20°C until further use.

The 3kb paired-end library was amplified in 9 emPCR reactions at 1cpb, and in 2 emPCRs at 0.5 cpb with the GS Titanium SV emPCR Kit (Lib-L) v2 (Roche). The yield of the 2 types of paired-end emPCR reactions was 7.8% and 11.2%, respectively, in the quality range of 5 to 20% expected from the Roche procedure. Both libraries were loaded onto GS Titanium PicoTiterPlates (PTP Kit 70×75, Roche) and pyrosequenced with the GS Titanium Sequencing Kit XLR70 and the GS FLX Titanium sequencer (Roche). The run was performed overnight and then analyzed on the cluster through the gsRunBrowser and Newbler assembler (Roche). A total of 969,014 passed filter wells were obtained and generated 274 Mb with a length average of 286 bp. The passed filter sequences were assembled using Newbler with 90% identity and 40bp as overlap. The final assembly identified 31 scaffolds and 129 contigs (>1,500 bp) and generated a genome size of 5.05Mb, which corresponds to a coverage of 54.2× coverage.

**Genome annotation**

Open Reading Frames (ORFs) were predicted using Prodigal [43] with default parameters but the predicted ORFs were excluded if they spanned a sequencing gap region. The predicted bacterial protein sequences were searched against the GenBank database [44] and the Clusters of Orthologous Groups (COG) databases using BLASTP. The tRNAscnSe tool [45] was used to find tRNA genes, whereas ribosomal RNAs were found by using RNAmmer [46] and BLASTN against the GenBank database. Lipoprotein signal peptides and numbers of transmembrane helices were predicted using SignalP [47] and TMHMM [48], respectively. ORFans were identified if their BLASTP E-value was lower than 1e-03 for alignment length greater than 80 amino acids. If alignment lengths were smaller than 80 amino acids, we used an E-value of 1e-05. Such parameter thresholds have already been used in previous works to define ORFans. To estimate the mean level of nucleotide sequence similarity at the genome level between *B. massiliensis* strain phR7, *B. laterosporus* strain LMG15441 (GenBank accession number AFRV00000000) and *B. brevis* strain NBRC100599 (GenBank accession number AP008955) and *B. agri* strain BAB-2500, we compared genomes two by two and determined the mean percentage of nucleotide sequence identity among orthologous ORFs using BLASTn. Orthologous genes were detected using the Proteinortho software [49].
**Genome properties**

The genome of *B. massiliensis* strain phR is 5,051,018 bp long (1 chromosome but no plasmid) with a G + C content of 53.1% (Figure 6 and Table 4). Of the 5,135 predicted genes, 5,051 were protein-coding genes, and 84 were RNAs. Three rRNA genes (one 16S rRNA, one 23S rRNA and one 5S rRNA) and 81 predicted tRNA genes were identified in the genome. A total of 3,793 genes (73.86%) were assigned a putative function. Three hundred and seventy-eight genes were identified as ORFans (7.36%). The remaining genes were annotated as hypothetical proteins. The properties and the statistics of the genome are summarized in Table 4. The distribution of genes into COGs functional categories is presented in Table 5.

**Figure 6.** Graphical circular map of the chromosome. From the outside in, the outer two circles shows open reading frames oriented in the forward (colored by COG categories) and reverse (colored by COG categories) direction, respectively. The third circle marks the rRNA gene operon (red) and tRNA genes (green). The fourth circle shows the G+C% content plot. The inner-most circle shows GC skew, purple indicating negative values whereas olive for positive values.
Table 4. Nucleotide content and gene count levels of the genome

| Attribute                          | Value    | % of total |
|------------------------------------|----------|------------|
| Genome size (bp)                   | 5,051,018|            |
| DNA coding region (bp)             | 4,481,706| 88.72      |
| DNA G+C content (bp)               | 2,682,091| 53.10      |
| Number of replicons                | 1        |            |
| Extrachromosomal elements          | 0        |            |
| Total genes                        | 5,135    | 100        |
| RNA genes                          | 84       | 1.63       |
| rRNA operons                       | 1        |            |
| Protein-coding genes               | 5,051    | 98.36      |
| Genes with function prediction     | 4,198    | 81.75      |
| Genes assigned to COGs             | 3,793    | 73.86      |
| Genes with peptide signals         | 354      | 6.89       |
| Genes with transmembrane helices   | 1,277    | 24.86      |
| CRISPR repeats                     | 0        |            |

\*The total is based on either the size of the genome in base pairs or the total number of protein coding genes in the annotated genome.

Table 5. Number of genes associated with the 25 general COG functional categories

| Code | Value | %age\(^a\) | Description                                           |
|------|-------|------------|-------------------------------------------------------|
| J    | 165   | 3.27       | Translation                                           |
| A    | 0     | 0          | RNA processing and modification                       |
| K    | 405   | 8.0        | Transcription                                         |
| L    | 176   | 3.48       | Replication, recombination and repair                 |
| B    | 1     | 0.02       | Chromatin structure and dynamics                      |
| D    | 33    | 0.65       | Cell cycle control, mitosis and meiosis              |
| Y    | 0     | 0          | Nuclear structure                                     |
| V    | 50    | 0.99       | Defense mechanisms                                    |
| T    | 233   | 4.61       | Signal transduction mechanisms                        |
| M    | 181   | 3.58       | Cell wall/membrane biogenesis                         |
| N    | 60    | 1.19       | Cell motility                                         |
| Z    | 0     | 0          | Cytoskeleton                                          |
| W    | 0     | 0          | Extracellular structures                              |
| U    | 42    | 0.83       | Intracellular trafficking and secretion               |
| O    | 111   | 2.20       | Posttranslational modification, protein turnover, chaperones |
| C    | 251   | 4.97       | Energy production and conversion                      |
| G    | 327   | 6.47       | Carbohydrate transport and metabolism                 |
| E    | 700   | 13.86      | Amino acid transport and metabolism                   |
| F    | 88    | 1.74       | Nucleotide transport and metabolism                   |
| H    | 159   | 3.15       | Coenzyme transport and metabolism                     |
| I    | 171   | 3.39       | Lipid transport and metabolism                        |
| P    | 317   | 6.28       | Inorganic ion transport and metabolism                |
| Q    | 150   | 2.97       | Secondary metabolites biosynthesis, transport and catabolism |
| R    | 578   | 11.44      | General function prediction only                      |
| S    | 319   | 6.32       | Function unknown                                      |
| -    | 1,258 | 24.91      | Not in COGs                                           |

\(^a\) The total is based on the total number of protein coding genes in the annotated genome.
Comparison with other *Brevibacillus* species genomes

Here, we compared the genome of *B. massiliensis* strain phR\(^T\) with those of *B. laterosporus* strain LMG15441, *B. brevis* strain NBRC100599 and *B. agri* strain BAB-2500. The draft genome of *B. massiliensis* is smaller than those of *B. laterosporus*, *B. agri* and *B. brevis* (5.05, 5.14, 5.39 and 6.29 Mb, respectively). *Brevibacillus massiliensis* has a higher G+C content than *Brevibacillus laterosporus* (53.10% vs 41.09%) and *Brevibacillus brevis* (53.10% vs 47.27%) but smaller than *Brevibacillus agri* (53.10% vs 53.5%).

*B. massiliensis* has a higher gene content than *B. laterosporus* (5,051 and 4,591, respectively) but lower than *B. agri* and *B. brevis* respectively (5,457 and 5.949 respectively). In addition, *B. massiliensis* shared 2,077, 2,500 and 2,453 orthologous genes with *B. laterosporus*, *B. brevis* and *B. agri* respectively. The average nucleotide sequence identity ranged from 67.17 to 78.81% among *Brevibacillus* species, and from 67.34 to 71.14% between *B. massiliensis* and other *Brevibacillus* species, thus confirming its new species status (Table 6).

|                | *B. massiliensis* | *B. laterosporus* | *B. brevis* | *B. agri* |
|----------------|-------------------|-------------------|-------------|-----------|
| *B. massiliensis* | 5,051             | 2,077             | 2,500       | 2,453     |
| *B. laterosporus* | 67.34             | 4,591             | 2,403       | 2,356     |
| *B. brevis*      | 69.36             | 68.38             | 5,949       | 2,779     |
| *B. agri*        | 71.14             | 67.17             | 78.81       | 5,457     |

†average percentage similarity of nucleotides corresponding to orthologous protein shared between genomes (below diagonal) and the numbers of proteins per genome (bold) [49].

Conclusion

On the basis of phenotypic, phylogenetic and genomic analyses, we formally propose the creation of *Brevibacillus massiliensis* sp. nov. which currently contains strain phR\(^T\) as its sole member; This bacterial strain was originally isolated in Marseille, France.

Description of *Brevibacillus massiliensis* sp. nov.

*Brevibacillus massiliensis* (ma.si.li.en'sis. L. gen. masc. n. *massiliensis*, pertaining to Massilia, the ancient Roman name for Marseille, France, where the type strain was isolated). Colonies are grey and 0.8 mm to 1 mm in diameter on blood-enriched Columbia agar. Cells are rod-shaped with a mean diameter of 0.74 µm and a mean length of 4.3µm with electron microscopy. Optimal growth is achieved aerobically. Weak growth was observed when cultures were grown under a 5% CO\(_2\). No growth is observed in microaerophilic or anaerobic conditions. Growth occurs between 30 and 45°C, with optimal growth occurring at 37°C. Cells stain Gram-positive, form endospores and are motile. Cells are positive for catalase, oxidase, alkaline phosphatase, cystine arylamidase, acid phosphatase, naphthol-AS-BI-phosphohydrolase and pyrazinamidase. Asaccharolytic. Cells are susceptible to penicillin G, amoxicillin, amoxicillin + clavulanic acid, ceftriaxone, imipenem, erythromycin, doxycycline, rifampicin, vancomycin, ciprofloxacin, gentamicin, nitrofurantoin and resistant to metronidazole and trimethoprim/sulfamethoxazole. The G+C content of the genome is 53.1%. The 16S rRNA and genome sequences are deposited in Genbank and EMBL under accession numbers JN837488 and CAGW00000000, respectively. The type strain phR\(^T\) (= CSUR P177 = DSM 25447) was isolated from the fecal flora of an obese patient in Marseille, France.
Brevibacillus massiliensis sp. nov.

Acknowledgements

The authors thank Mr. Julien Paganini at Xegen Company (www.xegen.fr) for automating the genomic annotation process. This study was funded by the Mediterranee Infection Foundation.

References

1. Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, Bittar F, Fournous G, Gimenez G, Maraninchi M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012; 18:1185-1193. PubMed

2. Genome Online Database. http://www.genomesonline.org/cgi-bin/GOLD/index.cgi

3. Tindall BJ, Rossello-Mora R, Busse HJ, Ludwig W, Kampfer P. Notes on the characterization of prokaryote strains for taxonomic purposes. Int J Syst Evol Microbiol 2010; 60:249-266. PubMed

4. Kokcha S, Mishra AK, Lagier JC, Million M, Leroy Q, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Bacillus timonensis sp. nov. Stand Genomic Sci 2012; 6:346-355. PubMed

5. Lagier JC, El Karkouri K, Nguyen TT, Armougom F, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Anaerococcus senegalensis sp. nov. Stand Genomic Sci 2012; 6:116-125. PubMed

6. Mishra AK, Gimenez G, Lagier JC, Robert C, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Alstipes senegalensis sp. nov. Stand Genomic Sci 2012; 6:304-314. PubMed

7. Lagier JC, Armougom F, Mishra AK, Nguyen TT, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Alstipes timonensis sp. nov. Stand Genomic Sci 2012; 6:315-324. PubMed

8. Mishra AK, Lagier JC, Robert C, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Clostridium senegalense sp. nov. Stand Genomic Sci 2012; 6:386-395. PubMed

9. Mishra AK, Lagier JC, Robert C, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Peptoniphilus timonensis sp. nov. [PubMed]. Stand Genomic Sci 2012; 7:1-11. PubMed

10. Mishra AK, Lagier JC, Rivet R, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Paeni bacillus senegalensis sp. nov. Stand Genomic Sci 2012; 7:70-81. PubMed

11. Lagier JC, Gimenez G, Robert C, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Herbaspirillum massiliense sp. nov. Stand Genomic Sci 2012; 7:200-209. PubMed

12. Roux V, El Karkouri K, Lagier JC, Robert C, Raoult D. Non-contiguous finished genome sequence and description of Kurthia massiliensis sp. nov. Stand Genomic Sci 2012; 7:233-245. PubMed

13. Kokcha S, Ramasamy D, Lagier JC, Robert C, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Brevibacterium senegalense sp. nov. Stand Genomic Sci 2012; 7:246-257. PubMed

14. Ramasamy D, Kokcha S, Lagier JC, N’Guyen TT, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Aeromicrobium massilense sp. nov. Stand Genomic Sci 2012; 7:258-270. PubMed

15. Lagier JC, Ramasamy D, Rivet R, Raoult D, Fournier PE. Non-contiguous finished genome sequence and description of Cellulomonas massiliensis sp. nov. Stand Genomic Sci 2012; 7:271-280. PubMed

16. Shida O, Takagi H, Kadowaki K, Komagata K. Proposal for two new genera, Brevibacillus gen. nov. and Aneurinibacillus gen. nov. Int J Syst Bacteriol 1996; 46:939-946. PubMed

17. List of Prokaryotic names with Standing in Nomenclature. http://www.bacterio.cict.fr

18. Logan NA, Forsyth G, Lebbe L, Goris J, Heyndrickx M, Balcaen A, Verhelst A, Falsen E, Ljungh A, Hansson HB, De Vos P. Polyphasic identification of Bacillus and Brevibacillus strains from clinical, dairy and industrial specimens and
19. Goto K, Fujita R, Kato Y, Asahara M, Yokota A. Reclassification of Brevibacillus brevis strains NCIMB 13288 and DSM 6472 (=NRRL NRS-887) as Aneurinibacillus danicus nov. sp. and Brevibacillus limnophilus sp. nov. Int J Syst Evol Microbiol 2004; 54:419-427. PubMed http://dx.doi.org/10.1099/ijs.0.02906-0

20. Allan RN, Lebbe L, Heyrman J, De Vos P, Buchanan CJ, Logan NA. Brevibacillus levickii sp. nov. and Aneurinibacillus terranovensis sp. nov., two novel thermoacidophiles isolated from geothermal soils of northern Victoria Land, Antarctica. Int J Syst Evol Microbiol 2005; 55:1039-1050. PubMed http://dx.doi.org/10.1099/ijs.0.63397-0

21. Baek SH, Im WT, Oh WH, Lee JS, Oh HM, Lee ST. Brevibacillus ginsengisoli sp. nov., a denitrifying bacterium isolated from soil of a ginseng field. Int J Syst Evol Microbiol 2006; 56:2665-2669. PubMed http://dx.doi.org/10.1099/ijs.0.64382-0

22. Kim MK, Sathiyaraj S, Pulla RK, Yang DC. Brevibacillus panachiumi sp. nov., a beta-glucosidase-producing bacterium. Int J Syst Evol Microbiol 2009; 59:1227-1231. PubMed http://dx.doi.org/10.1099/ijs.0.001248-0

23. Choi MJ, Bae JY, Kim KY, Kang H, Cha CJ. Brevibacillus fluminis sp. nov., isolated from sediment of estuarine wetland. Int J Syst Evol Microbiol 2010; 60:1595-1599. PubMed http://dx.doi.org/10.1099/ijs.0.012351-0

24. Takebe F, Hirota K, Nodasaka Y, Yumoto I. Brevibacillus nitrificans sp. nov., a nitrifying bacterium isolated from a microbiological agent for enhancing microbial digestion in sewage treatment tanks. Int J Syst Evol Microbiol 2012; 62:2121-2126. PubMed http://dx.doi.org/10.1099/ijs.0.032342-0

25. Sharma V, Singh PK, Midha S, Ranjan M, Korpole S, Patil PB. Genome Sequence of Brevibacillus laterosporus Strain GI-9. J Bacteriol 2012; 194:1279. PubMed http://dx.doi.org/10.1128/JB.06559-11

26. Andersson AM, Weiss N, Rainey F, Salkinoja-Salonen MS. Dust-borne bacteria in animal sheds, schools and children’s day care centres. J Appl Microbiol 1999; 86:622-634. PubMed http://dx.doi.org/10.1046/j.1365-2672.1999.00706.x

27. Lee L, Tin S, Kelley ST. Culture-independent analysis of bacterial diversity in a child-care fac-

28. Parvez N, Cornelius LK, Fader R. Brevibacillus brevis peritonitis. Am J Med Sci 2009; 337:297-299. PubMed http://dx.doi.org/10.1097/MAJ.0b013e3181891626

29. Tabbara KF, Juffali F, Matossian RM. Bacillus laterosporus endophthalmitis. Arch Ophthalmol 1977; 95:2187-2189. PubMed http://dx.doi.org/10.1001/archopht.1977.0445012093010

30. Woese CR, Kandler O, Wheelis ML. Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eukarya. Proc Natl Acad Sci USA 1990; 87:4576-4579. PubMed http://dx.doi.org/10.1073/pnas.87.12.4576

31. Gibbons NE, Murray RGE. Proposals Concerning the Higher Taxa of Bacteria. Int J Syst Bacteriol 1978; 28:1-6. http://dx.doi.org/10.1099/00207713-28-1-1

32. Garrity GM, Holt JG. The Road Map to the Manual. In: Garrity GM, Boone DR, Castenholz RW (eds), Bergey’s Manual of Systematic Bacteriology, Second Edition, Volume 1, Springer, New York, 2001, p. 119-169.

33. Murray RGE. The Higher Taxa, or, a Place for Everything…? In: Holt JG (ed), Bergey’s Manual of Systematic Bacteriology, First Edition, Volume 1, The Williams and Wilkins Co., Baltimore, 1984, p. 31-34.

34. Validation list no. 132. List of new names and new combinations previously effectively, but not validly published. Int J Syst Evol Microbiol 2010; 60:469-472. http://dx.doi.org/10.1099/ijs.0.022855-0

35. Ludwig W, Schleifer KH, Whitman WB. Class I. Bacilli class nov. In: De Vos P, Garrity G, Jones D, Krieg NR, Ludwig W, Rainey FA, Schleifer KH, Whitman WB (eds), Bergey’s Manual of Systematic Bacteriology, Second Edition, Volume 3, Springer-Verlag, New York, 2009, p. 19-20.

36. Skerman VBD, Sneth PHA. Approved list of bacterial names. Int J Syst Bacteriol 1980; 30:225-420. http://dx.doi.org/10.1099/00207713-30-1-225

37. Prévot AR. In: Haudero P, Ehringer G, Guillot G, Magrou J., Prévot AR, Rosset D, Urbain A (eds), Dictionnaire des Bactéries Pathogènes, Second Edition, Masson et Cie, Paris, 1953, p. 1-692.
Brevibacillus massiliensis sp. nov.

38. De Vos P, Ludwig W, Schleifer KH, Whitman WB. Family IV. Paenibacillaceae fam. nov. In: De Vos P, Garrity G, Jones D, Krieg NR, Ludwig W, Rainey FA, Schleifer KH, Whitman WB (eds), Bergey's Manual of Systematic Bacteriology, Second Edition, Volume 3, Springer-Verlag, New York, 2009, p. 269.

39. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29. PubMed http://dx.doi.org/10.1038/75556

40. Stackebrandt E, Ebers J. Taxonomic parameters revisited: tarnished gold standards. Microbiol Today 2006; 33:152-155.

41. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, Raoult D. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009; 49:543-551. PubMed http://dx.doi.org/10.1086/600885

42. Field D, Garrity G, Gray T, Morrison N, Selengut J, Sterk P, Tatusova T, Thomson N, Allen MJ, Angiuoli SV, et al. The minimum information about a genome sequence (MIGS) specification. Nat Biotechnol 2008; 26:541-547. PubMed http://dx.doi.org/10.1038/nbt1360

43. Prodigal. http://prodigalornl.gov

44. GenBank database. http://www.ncbi.nlm.nih.gov/genbank

45. Lowe TM, Eddy SR. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. Nucleic Acids Res 1997; 25:955-964. PubMed

46. Lagesen K, Hallin P, Rodland EA, Staerfeldt HH, Rognes T, Ussery DW. RNAmmer: consistent and rapid annotation of ribosomal RNA genes. Nucleic Acids Res 2007; 35:3100-3108. PubMed http://dx.doi.org/10.1093/nar/gkm160

47. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004; 340:783-795. PubMed http://dx.doi.org/10.1016/j.jmb.2004.05.028

48. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001; 305:567-580. PubMed http://dx.doi.org/10.1006/jmbi.2000.4315

49. Lechner M, Findeib S, Steiner L, Marz M, Stadler PF, Prohaska SJ. Proteinortho: Detection of (Co-)orthologs in large-scale analysis. BMC Bioinformatics 2011; 12:124. PubMed http://dx.doi.org/10.1186/1471-2105-12-124